A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use

DOI: 10.1086/502539
Infection Control and Hospital Epidemiology, 2005, 26, 273-8

#	Paper	IF	Citations
564	The new Clostridium difficile--what does it mean?. **2005**, 353, 2503-5		126
563	Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. **2005**, 41, 1254-60		774
562	Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. **2005**, 173, 1037-42		462
561	Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. **2005**, 294, 2989-95		714
560	Clostridium difficile: responding to a new threat from an old enemy. *Infection Control and Hospital Epidemiology*, **2005**, 26, 672-5	2	53
559	A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. **2005**, 353, 2442-9		1589
558	An epidemic, toxin gene-variant strain of Clostridium difficile. **2005**, 353, 2433-41		1674
557	The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. **2006**, 42 Suppl 2, S90-5		119
556	Bacterial enteric infections in children: etiology, clinical manifestations and antimicrobial therapy. **2006**, 4, 629-38		6
555	Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. **2006**, 74, 6339-47		194
554	Antimicrobial therapy of Clostridium difficile-associated diarrhea. **2006**, 90, 1141-63		25
553	Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. **2006**, 175, 745-8		161
552	Lack of association between the increased incidence of Clostridium difficile-associated disease and the increasing use of alcohol-based hand rubs. *Infection Control and Hospital Epidemiology*, **2006**, 27, 479-83	2	102
551	An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease. **2006** , 35, 315-35		51
550	Risk factors for Clostridium difficile toxin-positive nosocomial diarrhoea. **2006**, 28, 231-7		39
549	Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial. **2006**, 19, 3-12		35
548	Levofloxacin use in the elderly: focus on pneumonia. **2006**, 2, 371-382		2

547	Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea. **2006**, 40, 249-55	79
546	Bibliography. Current world literature. Nosocomial and hospital-related infections. **2006**, 19, 386-96	
545	Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. **2006**, 24, 613-9	116
544	Update on Clostridium difficile. **2006**, 9, 265-71	16
543	Probiotics and prebiotics for gastrointestinal infections. **2006**, 8, 103-9	16
542	Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists. **2006**, 26, 299-311	48
541	Changing Epidemiology of Clostridium difficile-Associated Disease. **2006**, 14, 296-302	6
540	A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. **2006**, 166, 2518-24	92
539	A survey of physician's attitudes regarding management of severe group A streptococcal infections. **2006**, 38, 977-82	9
538	Fluoroquinolones and anaerobes. **2006**, 42, 1598-607	57
537	Quinolones: A Nosocomial Risk Factor for Clostridium DifficileâÆAssociated Diarrhea. **2006**, 139, 47-49	
536	Improving the treatment of Clostridium difficile-associated disease: where should we start?. **2006**, 43, 553-5	17
535	High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. **2006**, 58, 1264-7	77
534	Nitazoxanide for the treatment of Clostridium difficile colitis. **2006**, 43, 421-7	196
533	Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?. **2006**, 50, 3216-9	38
532	Past, present, and future therapies for Clostridium difficile-associated disease. **2006**, 40, 2155-63	37
531	Multilocus variable-number tandem-repeat analysis for investigation of Clostridium difficile transmission in Hospitals. **2006**, 44, 2558-66	103
530	In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. **2007**, 51, 2716-9	186

529	tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. **2007**, 45, 215-21		157
528	Systematic review of the risk of enteric infection in patients taking acid suppression. *American Journal of Gastroenterology*, **2007**, 102, 2047-56; quiz 2057	0.7	426
527	The changing face of Clostridium difficile: what treatment options remain?. *American Journal of Gastroenterology*, **2007**, 102, 2789-92	0.7	8
526	Does emergency colectomy reduce mortality in patients with Clostridium difficile-associated disease?. **2007**, 4, 542-3		2
525	Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. **2007**, 45, 1266-73		206
524	Clostridium difficile is the Most Common Identifiable Cause of Infectious Colitis. **2007**, 15, 49-53		
523	[Dramatic increase of Clostridium difficile-associated diarrhea in Germany: has the new strain PCR-ribotype 027 already reached us?]. **2007**, 132, 223-8		7
522	Treatment strategies for recurrent and refractory Clostridium difficile-associated diarrhea. **2007**, 1, 295-305		2
521	Clostridium difficile colitis. **2007**, 20, 13-7		15
520	The challenges posed by reemerging Clostridium difficile infection. **2007**, 45, 222-7		119
519	A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. **2007**, 44, 238-44		158
518	Multicenter treatment and outcome evaluation of aspiration syndromes in critically ill patients. **2007**, 41, 549-55		20
517	Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. **2007**, 45, 992-8		415
516	Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice. **2007**, 51, 2674-8		55
515	Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system. **2007**, 45, 1141-51		88
514	Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. **2007**, 45, 695-703		124
513	Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. **2007**, 45 Suppl 2, S112-21		255
512	Asymptomatic Clostridium difficile colonization: is this the tip of another iceberg?. **2007**, 45, 999-1000		21

511	Confronting Clostridium difficile in inpatient health care facilities. **2007**, 45, 1274-6	13
510	Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea. **2007**, 45, 1646-7; author reply 1649-51	8
509	Part III: Colorectal Disorders. **2007**, 439-474	
508	Probiotics for preventing and treating nosocomial infections: review of current evidence and recommendations. **2007**, 132, 286-94	45
507	Clostridium difficile-Associated Disease in the New Millennium. **2007**, 15, 299-315	5
506	Update on Clostridium difficile associated disease. **2007**, 23, 4-9	45
505	Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. **2007**, 245, 267-72	275
504	Clostridium difficile: changing epidemiology and new treatment options. **2007**, 20, 376-83	103
503	Analysis of 30-day mortality for clostridium difficile-associated disease in the ICU setting. **2007**, 132, 418-24	112
502	Accuracy of ICD-9 coding for Clostridium difficile infections: a retrospective cohort. **2007**, 135, 1010-3	92
501	Implications of the changing face of Clostridium difficile disease for health care practitioners. **2007**, 35, 237-53	90
500	Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea. **2007**, 35, 131-7	115
499	Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. **2007**, 35, 315-8	121
498	Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: Position statement from the Joint SHEA and APIC Task Force. **2007**, 35, 73-85	111
497	Impact of a fluoroquinolone restriction policy in an elderly population. **2007**, 120, 893-900	35
496	Use of intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis. **2007**, 5, 48-51	25
495	Actualit'des infections digestives ˆClostridium difficile, France, 2007. **2007**, 2007, 41-48	
494	The burden of Clostridium difficile in surgical patients in the United States. **2007**, 8, 557-66	128

493	Antimicrobial Resistance: Problem Pathogens and Clinical Countermeasures. *Infectious Disease and Therapy*, **2007**,		
492	Update on clindamycin in the management of bacterial, fungal and protozoal infections. **2007**, 8, 2401-44		23
491	Bench-to-bedside review: Clostridium difficile colitis. **2008**, 12, 203		43
490	Safety concerns with fluoroquinolones. **2007**, 41, 1859-66		159
489	Clostridium difficile in the long-term care setting. **2007**, 8, 290-9		19
488	Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. *Infection Control and Hospital Epidemiology*, **2007**, 28, 198-201	2	79
487	Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. *Infection Control and Hospital Epidemiology*, **2007**, 28, 123-30	2	118
486	Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004. *Infection Control and Hospital Epidemiology*, **2007**, 28, 131-9	2	128
485	Recommendations for surveillance of Clostridium difficile-associated disease. *Infection Control and Hospital Epidemiology*, **2007**, 28, 140-5	2	477
484	An outbreak of severe Clostridium difficile-associated disease possibly related to inappropriate antimicrobial therapy for community-acquired pneumonia. *Infection Control and Hospital Epidemiology*, **2007**, 28, 212-4	2	55
483	Legislative mandates for use of active surveillance cultures to screen for methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: position statement from the Joint SHEA and APIC Task Force. *Infection Control and Hospital Epidemiology*, **2007**, 28, 249-60	2	100
482	Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. *Infection Control and Hospital Epidemiology*, **2007**, 28, 932-40	2	102
481	Clostridium difficile-associated disease in patients in a small rural hospital. *Infection Control and Hospital Epidemiology*, **2007**, 28, 1236-9	2	5
480	Diarrheal diseases in the elderly. **2007**, 23, 833-56, vii		39
479	Risk of Clostridium difficile-associated disease among patients receiving proton-pump inhibitors in a Quebec medical intensive care unit. *Infection Control and Hospital Epidemiology*, **2007**, 28, 1305-7	2	47
478	Clostridium difficile--associated disease in a setting of endemicity: identification of novel risk factors. **2007**, 45, 1543-9		214
477	Clostridium difficile-associated disease: changing epidemiology and implications for management. **2007**, 67, 487-502		30
476	Clostridium difficile: The evolving story. **2007**, 18, 341-5		3

475	A case of recurrent Clostridium difficile diarrhea. **2007**, 22, 249-53		1
474	Is it Clostridium difficile infection or something else? A case-control study of 352 hospitalized patients with new-onset diarrhea. *Southern Medical Journal*, **2007**, 100, 782-6	0.6	11
473	Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. *Clinical Microbiology and Infection*, **2007**, 13, 1048-57	9.5	227
472	Clostridium difficile: recent epidemiologic findings and advances in therapy. **2007**, 27, 1029-39		36
471	Identification, optimal management, and infection control measures for Clostridium difficile-associated disease in long-term care. **2007**, 28, 171-81; quiz 182		10
470	Colonization and impact of disease and other factors on intestinal microbiota. **2007**, 52, 2069-77		68
469	Review: Clostridium difficile-associated disorders/diarrhea and Clostridium difficile colitis: the emergence of a more virulent era. **2007**, 52, 1071-5		18
468	Clostridium difficile: emergence of hypervirulence and fluoroquinolone resistance. **2007**, 35, 300-7		67
467	Clostridium-difficile-assoziierte Erkrankungen. **2007**, 2, 53-63		2
466	Fucoidin prevents Clostridium difficile toxin-A-induced ileal enteritis in mice. **2008**, 53, 990-6		10
465	Clostridium difficile infection: a surgical disease in evolution. **2008**, 12, 1512-7		26
464	Clostridium difficile infection: a critical overview. **2008**, 10, 165-73		13
463	Clostridium difficile and inflammatory bowel disease. **2008**, 14, 1432-42		157
462	Could Clostridium difficile delay dental treatment for geriatric patients?. **2008**, 28, 223		
461	Infection control measures to limit the spread of Clostridium difficile. *Clinical Microbiology and Infection*, **2008**, 14 Suppl 5, 2-20	9.5	183
460	Single-dose cefuroxime with gentamicin reduces Clostridium difficile-associated disease in hip-fracture patients. **2008**, 70, 21-6		35
459	Clostridium difficile--more difficult than ever. **2008**, 359, 1932-40		1040
458	Cefepime: a reappraisal in an era of increasing antimicrobial resistance. **2008**, 6, 805-24		85

457	Treatment of Clostridium difficile infection. **2008**, 46 Suppl 1, S32-42		204
456	Measures to control and prevent Clostridium difficile infection. **2008**, 46 Suppl 1, S43-9		233
455	Clostridium difficile-positive stools: a retrospective identification of risk factors. **2008**, 36, 488-91		7
454	[Update on Clostridium difficile infections]. **2008**, 29, 209-14		12
453	[Clostridium difficile infections: an unexpected re-emergence]. **2008**, 56, 6-9		1
452	Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. **2008**, 26, 3404-9		43
451	The Utility of Fluoroquinolones in the Critically Ill. **2008**, 21, 346-355		
450	Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. *Infection Control and Hospital Epidemiology*, **2008**, 29, 44-50	2	122
449	Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) acquisition in roommate contacts of patients colonized or infected with MRSA in an acute-care hospital. *Infection Control and Hospital Epidemiology*, **2008**, 29, 600-6	2	47
448	Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa susceptibility to quinolones and other antimicrobial agents. *Infection Control and Hospital Epidemiology*, **2008**, 29, 716-22	2	20
447	Strategies to prevent clostridium difficile infections in acute care hospitals. *Infection Control and Hospital Epidemiology*, **2008**, 29 Suppl 1, S81-92	2	153
446	Prevention and treatment of health care-acquired infections. **2008**, 92, 295-313, viii		10
445	Clostridium difficile infection in critically injured trauma patients. **2008**, 9, 497-501		19
444	Hypervirulent antibiotic-resistant Clostridium difficile in Europe. **2008**, 20, 210-212		
443	Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. **2008**, 24, 329-33		60
442	Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. *Journal of Medical Microbiology*, **2008**, 57, 784-789	3.2	95
441	Short- and long-term attributable costs of Clostridium difficile-associated disease in nonsurgical inpatients. **2008**, 46, 497-504		154
440	Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile. **2008**, 52, 2190-5		31

439	Comparison of real-time PCR for detection of the tcdC gene with four toxin immunoassays and culture in diagnosis of Clostridium difficile infection. **2008**, 46, 1996-2001		171
438	What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?. **2009**, 63, 238-42		48
437	Medication-related complications in the trauma patient. **2008**, 23, 91-108		9
436	The changing spectrum of clostridium difficile associated disease: implications for dentistry. **2008**, 139, 42-7		5
435	Antibiotic-associated diarrhea: epidemiology, trends and treatment. **2008**, 3, 563-78		190
434	Clinical review of the management of fulminant clostridium difficile infection. *American Journal of Gastroenterology*, **2008**, 103, 3195-203; quiz 3204	0.7	77
433	Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. **2008**, 52, 3180-7		123
432	Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy. **2008**, 47 Suppl 1, S14-20		63
431	Antimicrobial-associated risk factors for Clostridium difficile infection. **2008**, 46 Suppl 1, S19-31		442
430	Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. **2008**, 47, 56-62		128
429	Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006. **2008**, 46, 2999-3004		76
428	The economics of Clostridium difficile-associated disease for providers and payers. **2008**, 46, 505-6		4
427	Antibiotic use and other risk factors at hospital level for outbreaks with Clostridium difficile PCR ribotype 027. *Journal of Medical Microbiology*, **2008**, 57, 709-716	3.2	19
426	Measuring the severity of Clostridium difficile infection: implications for management and drug development. **2008**, 6, 897-908		12
425	Attributable outcomes of endemic Clostridium difficile-associated disease in nonsurgical patients. **2008**, 14, 1031-8		132
424	« Clostridium difficile » et pathologie digestive. **2008**, 5, 1-11		2
423	Measuring the incidence of Clostridium difficile-associated diarrhoea in a group of Western Australian hospitals. **2008**, 13, 56-62		7
422	Clostridium difficile infection in solid organ transplant recipients. **2008**, 13, 592-600		75

421	Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. **2008**, 22, 761-6		53
420	[Clinical characteristics and changing epidemiology of Clostridium difficile-associated disease (CDAD)]. **2009**, 54, 13-9		13
419	Proton pump inhibitor use and enteric infections. *American Journal of Gastroenterology*, **2009**, 104 Suppl 2, S10-6	0.7	62
418	Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. **2009**, 48, 568-76		214
417	High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. **2009**, 48, 425-9		122
416	Clinical risk factors for severe Clostridium difficile-associated disease. **2009**, 15, 415-22		176
415	Swine flu and antibiotics. **2009**, 64, 889-94		18
414	Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. **2009**, 48, e41-6		145
413	Severe pseudomembranous colitis after moxifloxacin use: a case series. **2009**, 43, 123-8		5
412	Microbiology and Aging. **2009**,		7
411	The management of Clostridium difficile infection. **2009**, 91, 87-110		9
410	Antibiotics for community-acquired pneumonia. **2009**, 64, 1123-5		14
409	Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. **2009**, 53, 2463-8		29
408	Quasiexperimental study of the effects of antibiotic use, gastric acid-suppressive agents, and infection control practices on the incidence of Clostridium difficile-associated diarrhea in hospitalized patients. **2009**, 53, 2082-8		41
407	Role of hand hygiene in healthcare-associated infection prevention. **2009**, 73, 305-15		553
406	Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile. **2009**, 73, 185-7		11
405	Stethoscopes: potential vectors of Clostridium difficile. **2009**, 73, 187-9		19
404	An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse. **2009**, 29, 736-43		38

403	Avoiding pitfalls: what an endoscopist should know in liver transplantation--part II. **2009**, 54, 1386-402		19
402	Evolving concepts in Clostridium difficile colitis. **2009**, 11, 400-5		15
401	Predictors of serious complications due to Clostridium difficile infection. **2009**, 29, 635-42		47
400	Clostridium difficile infection: new developments in epidemiology and pathogenesis. **2009**, 7, 526-36		1007
399	Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 80 and older. **2009**, 57, 659-62		38
398	The potential of probiotic fermented milk products in reducing risk of antibiotic-associated diarrhoea and Clostridium difficile disease. **2009**, 62, 461-471		4
397	Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. *Clinical Microbiology and Infection*, **2009**, 15, 427-34	9.5	58
396	Healthcare-associated Infections: epidemiology, prevention, and therapy. **2009**, 76, 84-94		23
395	[Epidemic risk of disease associated with a new strain of Clostridium difficile]. **2009**, 27, 278-84		3
394	What is on that keyboard? Detecting hidden environmental reservoirs of Clostridium difficile during an outbreak associated with North American pulsed-field gel electrophoresis type 1 strains. **2009**, 37, 15-9		75
393	Analysis of an outbreak of Clostridium difficile infection controlled with enhanced infection control measures. **2009**, 37, 458-64		26
392	National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. **2009**, 37, 263-70		106
391	Antimicrobial resistance in Clostridium difficile. **2009**, 34, 516-22		127
390	Reining in recurrent Clostridium difficile infection--who's at risk?. **2009**, 136, 1152-4		15
389	Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. **2009**, 136, 1913-24		276
388	What is the role of antimicrobial resistance in the new epidemic of Clostridium difficile?. **2009**, 33 Suppl 1, S9-12		17
387	Clostridium difficile and fluoroquinolones: is there a link?. **2009**, 33 Suppl 1, S29-32		16
386	Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. **2009**, 10, R102		342

385	Clostridium difficile infection in the intensive care unit. **2009**, 23, 727-43		51
384	Does PPI therapy predispose to Clostridium difficile infection?. **2009**, 6, 555-7		19
383	Gastrointestinal side effects of prescription medications in the older adult. **2009**, 43, 103-10		23
382	Risk factors for mortality following emergency colectomy for fulminant Clostridium difficile infection. **2009**, 52, 400-5		61
381	Epidemiology and outcomes of clostridium difficile-associated disease among patients on prolonged acute mechanical ventilation. **2009**, 136, 752-758		36
380	The antibiotic challenge: changing clinical management of infections. **2009**, 22, 22-6		9
379	Identification of risk factors for the development of clostridium difficile-associated diarrhea following treatment of polymicrobial surgical infections. **2010**, 251, 722-7		17
378	Colectomy for Fulminant Clostridium difficile Colitis: Predictors of Mortality. **2010**, 2010, 66-67		1
377	Characterization of Clostridium difficile Infection and Analysis of Recovered Isolates in a Community Hospital Population in Baltimore, Maryland. **2010**, 18, 383-388		2
376	Clostridium difficile infection. **2010**, 340, 247-52		96
375	[Clostridium difficile-associated infections. How dangerous are the new strains?]. **2010**, 51, 154-60		1
374	Le microbiote dans les diarrhès infectieuses. **2010**, 34, 31-40		1
373	[The microbiota and infectious diarrhea]. **2010**, 34 Suppl 1, S29-36		4
372	Comparative analysis of the extracellular proteomes of two Clostridium sordellii strains exhibiting contrasting virulence. **2010**, 16, 454-60		7
371	Concordance between two enzyme immunoassays for the detection of Clostridium difficile toxins. **2010**, 41, 92-6		5
370	Comparative effectiveness of macrolides and quinolones for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD). **2010**, 5, 261-7		20
369	A review of mortality due to Clostridium difficile infection. **2010**, 61, 1-8		108
368	Clostridium difficile in food--innocent bystander or serious threat?. *Clinical Microbiology and Infection*, **2010**, 16, 3-10	9.5	107

367	Risk Factors for the Development of Clostridium difficile-associated Colitis after Colorectal Cancer Surgery. **2010**, 26, 329-33	25
366	Infections of the gastrointestinal tract. **2010**, 593-607	
365	Colectomy for fulminant Clostridium difficile colitis: predictors of mortality. **2010**, 76, 418-21	35
364	Article Commentary: Clostridium difficile and the Surgeon. **2010**, 76, 235-244	12
363	Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. **2010**, 30, 491-7	60
362	Clostridium difficile-associated diarrhea in a tertiary care medical center. **2010**, 23, 363-7	4
361	[Change of Clostridium difficile colitis during recent 10 years in Korea]. **2010**, 55, 169-74	21
360	Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. **2010**, 5, 539-48	17
359	Comment: The relationship between inpatient fluoroquinolone use and Clostridium difficile-associated disease. **2010**, 44, 1855-6	2
358	Rifaximin therapy for metronidazole-unresponsive Clostridium difficile infection: a prospective pilot trial. **2010**, 3, 221-5	42
357	Clostridium difficile infections among hospitalized children, United States, 1997-2006. **2010**, 16, 604-9	194
356	The changing epidemiology of Clostridium difficile infections. **2010**, 23, 529-49	630
355	Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. **2010**, 50, 194-201	235
354	Multilocus variable-number tandem-repeat analysis and multilocus sequence typing reveal genetic relationships among Clostridium difficile isolates genotyped by restriction endonuclease analysis. **2010**, 48, 412-8	43
353	Empiric therapy for gram-negative pathogens in nosocomial and health care-associated pneumonia: starting with the end in mind. **2010**, 25, 259-70	12
352	Clostridium difficile isolates resistant to fluoroquinolones in Italy: emergence of PCR ribotype 018. **2010**, 48, 2892-6	76
351	Unusual manifestations of Clostridium difficile infection. **2010**, 11, 333-7	14
350	In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. **2010**, 63, 355-8	37

349	Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions. **2010**, 1, 234-242		73
348	Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. **2010**, 6, e1001061		92
347	Multihospital outbreak of Clostridium difficile infection, Cleveland, Ohio, USA. **2010**, 16, 827-9		14
346	Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. *Infection Control and Hospital Epidemiology*, **2010**, 31, 21-7	2	213
345	Multicenter study of surveillance for hospital-onset Clostridium difficile infection by the use of ICD-9-CM diagnosis codes. *Infection Control and Hospital Epidemiology*, **2010**, 31, 262-8	2	58
344	Is high consumption of antibiotics associated with Clostridium difficile polymerase chain reaction-ribotype 027 infections in France?. *Infection Control and Hospital Epidemiology*, **2010**, 31, 302-5	2	8
343	Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands. *Infection Control and Hospital Epidemiology*, **2010**, 31, 565-70	2	105
342	Epidemiological patterns and hospital characteristics associated with increased incidence of Clostridium difficile infection in Quebec, Canada, 1998-2006. *Infection Control and Hospital Epidemiology*, **2010**, 31, 939-47	2	35
341	Quantifying interhospital patient sharing as a mechanism for infectious disease spread. *Infection Control and Hospital Epidemiology*, **2010**, 31, 1160-9	2	56
340	Guâs de prâtica clînica para la infecciñ porClostridium difficileen adultos: actualizaciñ 2010 realizada por la Sociedad de Salud Epidemiolâgica de Norteamârica (SHEA) y la Sociedad de Enfermedades Infecciosas de Norteamârica (IDSA). *Infection Control and Hospital Epidemiology*, **2010**, 31, T1-T28	2	3
339	Clostridium difficile. **2010**, 30, 329-42		17
338	Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). *Infection Control and Hospital Epidemiology*, **2010**, 31, 431-55	2	2383
337	The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. **2010**, 4, 409-16		124
336	Detection of gyrA and gyrB mutations in Clostridium difficile isolates by real-time PCR. **2010**, 24, 61-7		12
335	Clostridium difficile colitis: a retrospective study of incidence and severity before and after institution of an alcohol-based hand rub policy. **2010**, 38, 523-8		18
334	Safety and tolerability of commonly prescribed oral antibiotics for the treatment of respiratory tract infections. **2010**, 123, S26-38		33
333	Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. **2010**, 10, 395-404		136
332	Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. **2010**, 11, 1569-78		44

331	Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. **2011**, 52, e56-93		1797
330	Automated surveillance of Clostridium difficile infections using BioSense. *Infection Control and Hospital Epidemiology*, **2011**, 32, 26-33	2	19
329	Multihospital outbreak of Clostridium difficile ribotype 027 infection: epidemiology and analysis of control measures. *Infection Control and Hospital Epidemiology*, **2011**, 32, 210-9	2	47
328	Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. *Infection Control and Hospital Epidemiology*, **2011**, 32, 201-6	2	234
327	Development and validation of a Clostridium difficile infection risk prediction model. *Infection Control and Hospital Epidemiology*, **2011**, 32, 360-6	2	72
326	Clostridium difficile outbreak strain BI is highly endemic in Chicago area hospitals. *Infection Control and Hospital Epidemiology*, **2011**, 32, 897-902	2	26
325	Best strategies in recurrent or persistent Clostridium difficile infection. **2011**, 12, 235-9		35
324	[Risk factors for Clostridium difficile infections in hospitalized patients]. **2011**, 137, 575-80		9
323	The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge. **2011**, 58, 4-20		33
322	Pathogenic C difficile is here (and everywhere) to stay. **2011**, 377, 8-9		15
321	[Not Available]. **2011**, 153, 45-50		0
320	Antibiotic Collateral Damage: Resistance and Antibiotic-Associated Diarrhea. **2011**, 46, 758-768		3
319	Interaction of Age and Levofloxacin Exposure on the Incidence of Clostridium difficile Infection. **2011**, 19, 262-264		2
318	Endoscopic fecal microbiota transplantation: "first-line" treatment for severe clostridium difficile infection?. **2011**, 45, 655-7		59
317	Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. **2011**, 34, 1269-81		283
316	CSI: a severity index for Clostridium difficile infection at the time of admission. **2011**, 79, 151-4		49
315	Control of an outbreak of diarrhoea in a vascular surgery unit caused by a high-level clindamycin-resistant Clostridium difficile PCR ribotype 106. **2011**, 79, 242-7		14
314	Biology of Clostridium difficile: implications for epidemiology and diagnosis. **2011**, 65, 501-21		176

313	Clostridium difficile infection in an endemic setting in the Netherlands. **2011**, 30, 587-93	36
312	Rapid diagnosis of Clostridium difficile infection by multiplex real-time PCR. **2011**, 30, 1279-85	26
311	Impact of an antibiotic restriction program on antibiotic utilization in the treatment of community-acquired pneumonia in a Veterans Affairs Medical Center. **2011**, 39, 53-8	7
310	Clostridium difficile colitis: factors associated with outcome and assessment of mortality at a national level. **2011**, 15, 1548-55	39
309	Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. **2011**, 11, 194	119
308	Fidaxomicin: first-in-class macrocyclic antibiotic. **2011**, 9, 767-77	35
307	Fourteen-genome comparison identifies DNA markers for severe-disease-associated strains of Clostridium difficile. **2011**, 49, 2230-8	35
306	Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. **2011**, 66, 2168-74	140
305	The impact of ICD-9-CM code rank order on the estimated prevalence of Clostridium difficile infections. **2011**, 53, 20-5	45
304	Rifaximin Is Effective for the Treatment of Clostridium difficile-Associated Diarrhea: Results of an Open-Label Pilot Study. **2011**, 2011, 106978	25
303	Sustained reduction in antimicrobial use and decrease in methicillin-resistant Staphylococcus aureus and Clostridium difficile infections following implementation of an electronic medical record at a tertiary-care teaching hospital. **2011**, 66, 205-9	42
302	Multidrug resistance in European Clostridium difficile clinical isolates. **2011**, 66, 2227-34	134
301	Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. **2011**, 52, 427-31	516
300	The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. **2011**, 7, e1002317	109
299	Harnessing the glucosyltransferase activities of Clostridium difficile for functional studies of toxins A and B. **2011**, 49, 2933-41	13
298	Enteric Clostridium Infections. **2011**, 162-166	
297	The emergence of Clostridium difficile infection among peripartum women: a case-control study of a C. difficile outbreak on an obstetrical service. **2011**, 2011, 267249	20
296	Anaerobic microbiology: time to rejuvenate. **2012**, 30, 3-5	4

295	Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. **2012**, 55 Suppl 2, S93-103		188
294	Clostridium difficile Infection in Children: Current State and Unanswered Questions. **2012**, 1, 230-43		49
293	Pathology consultation on detection of Clostridium difficile. **2012**, 137, 10-5		5
292	[Probiotics for the prevention of antibiotic-induced diarrhea]. **2012**, 50, 1089-95		4
291	Antibiotic heterogeneity optimizes antimicrobial prescription and enables resistant pathogen control in the intensive care unit. **2012**, 13, 194-202		10
290	The epidemiology of community-acquired Clostridium difficile infection: a population-based study. *American Journal of Gastroenterology*, **2012**, 107, 89-95	0.7	420
289	The Clostridium difficile spo0A gene is a persistence and transmission factor. **2012**, 80, 2704-11		240
288	In vivo selection of moxifloxacin-resistant Clostridium difficile. **2012**, 56, 2788-9		2
287	Association of relapse of Clostridium difficile disease with BI/NAP1/027. **2012**, 50, 4078-82		100
286	Clostridium difficile colitis: increasing incidence, risk factors, and outcomes in solid organ transplant recipients. **2012**, 93, 1051-7		88
285	Evaluating contemporary antibiotics as a risk factor for Clostridium difficile infection in surgical trauma patients. **2012**, 72, 691-5		15
284	Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. **2012**, 343, 277-80		38
283	Clinical risk factors for Clostridium difficile-associated diseases. **2012**, 16, 256-261		4
282	Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. **2012**, 56, 2037-47		22
281	Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting. **2012**, 44, 243-9		16
280	Clostridium difficile Infection. **2012**, 1, e69-e86		0
279	Underestimation of Clostridium difficile infection among clinicians: an international survey. **2012**, 31, 2439-44		22
278	Pilot study to measure cleaning effectiveness in health care. **2012**, 40, 477-8		11

277	Clostridium difficile infection in the pediatric surgery population. **2012**, 47, 1385-9		7
276	Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. **2012**, 99, 1501-13		111
275	Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. *American Journal of Gastroenterology*, **2012**, 107, 1011-9	0.7	386
274	Detection, treatment, and prevention of Clostridium difficile infection. **2012**, 10, 581-92		73
273	Assessing colectomies due to Clostridium difficile infection: increases in the community, but not in the referral center. **2012**, 40, 778-80		2
272	Changing incidence and clinical manifestations of Clostridium difficile-associated diarrhea detected by combination of glutamate dehydrogenase and toxin assay in Northern Taiwan. **2012**, 45, 287-95		24
271	Clostridium difficile infection: new insights into management. **2012**, 87, 1106-17		98
270	Immune responses to Clostridium difficile infection. **2012**, 18, 658-66		62
269	Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. **2012**, 10, 225-33		147
268	Epidemiology, diagnosis and treatment of Clostridium difficile infection. **2012**, 10, 1405-23		53
267	Crisis in hospital-acquired, healthcare-associated infections. **2012**, 63, 359-71		70
266	PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics. **2012**, 16, 2267-73		25
265	Enfermedad asociada a Clostridium difficile: prevalencia y diagnóstico por laboratorio. **2012**, 16, 211-222		2
264	Novel management strategies in the treatment of severe Clostridium difficile infection. **2012**, 46, 111-35		5
263	Clostridium difficile outbreaks: prevention and treatment strategies. **2012**, 5, 55-64		20
262	Clinical risk factors for Clostridium difficile-associated diseases. **2012**, 16, 256-61		20
261	Michigan Clostridium difficile hospital discharges: frequency, mortality, and charges, 2002-2008. **2012**, 127, 62-71		13
260	A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs. **2012**, 32, 129-34		22

259	Fulminant Clostridium difficile toxic megacolon in a pediatric heart transplant recipient. **2012**, 16, E30-4	4
258	TcdB from hypervirulent Clostridium difficile exhibits increased efficiency of autoprocessing. **2012**, 84, 66-76	31
257	Effect of new antimicrobial agents on the ecological balance of human microflora. **2012**, 18, 249-53	47
256	Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. **2012**, 34, 1-13	61
255	Effects of adenosine AâÅ receptor activation and alanyl-glutamine in Clostridium difficile toxin-induced ileitis in rabbits and cecitis in mice. **2012**, 12, 13	19
254	Antimicrobial susceptibility profiles of human and piglet Clostridium difficile PCR-ribotype 078. **2013**, 2, 14	38
253	Comparative transcription analysis and toxin production of two fluoroquinolone-resistant mutants of Clostridium perfringens. **2013**, 13, 50	9
252	Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. **2013**, 38, 1-11	37
251	The impact of cefepime as first line therapy for neutropenic fever on Clostridium difficile rates among hematology and oncology patients. **2013**, 24, 79-81	15
250	Acid suppression and the risk of Clostridium difficile infection. **2013**, 163, 627-30	13
249	Hand hygiene and healthcare system change within multi-modal promotion: a narrative review. **2013**, 83 Suppl 1, S3-10	50
248	Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection. **2013**, 42, 553-8	21
247	Levofloxacin for the treatment of pyelonephritis. **2013**, 14, 1241-53	7
246	Community-associated Clostridium difficile infection: how real is it?. **2013**, 24, 121-3	38
245	Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. **2013**, 13, 376	30
244	Overview of severe Clostridium difficile infection. **2013**, 29, 827-39	18
243	Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. **2013**, 51, 1465-73	69
242	Clostridium difficile healthcare-associated epidemics. **2013**, 45, 6-7	1

241	Clostridium difficile infection in the twenty-first century. **2013**, 2, e62		70
240	Emergence and global spread of epidemic healthcare-associated Clostridium difficile. **2013**, 45, 109-13		509
239	Clostridium difficile infection increases mortality risk in lung transplant recipients. **2013**, 32, 1020-6		33
238	Fulminant Clostridium difficile colitis: a complication of perioperative antibiotic prophylaxis. **2013**, 71, 1880-5		17
237	Variations in virulence and molecular biology among emerging strains of Clostridium difficile. **2013**, 77, 567-81		64
236	Assessment of treatment patterns and patient outcomes before vs after implementation of a severity-based Clostridium difficile infection treatment policy. **2013**, 85, 28-32		23
235	Clostridium difficile: infecção e ribotipos. **2013**, 20, 240-242		
234	Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection. **2013**, 85, 22-7		17
233	Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. *American Journal of Gastroenterology*, **2013**, 108, 478-98; quiz 499	0.7	1147
232	Evaluation and Management of Bacterial and Fungal Infections Occurring in Patients with a Hematological Malignancy: A 2011 Update. **2013**, 1165-1191		
231	Clostridium difficile infection. **2013**, 50, 302-37		26
230	Bed occupancy rates and hospital-acquired Clostridium difficile infection: a cohort study. *Infection Control and Hospital Epidemiology*, **2013**, 34, 1062-9	2	10
229	Epidemiology of Clostridium difficile infection. **2013**, 26, 464-75		143
228	Treatment of infection: recent trial results. **2013**, 3, 875-886		4
227	Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment of Clostridium difficile infections. **2013**, 11, 767-76		7
226	Prevalence and risk factors of Clostridium difficile - associated diarrhea in Iranian hospitalized patients. **2013**, 6, 554		3
225	Clostridium difficile 027/BI/NAP1 encodes a hypertoxic and antigenically variable form of TcdB. **2013**, 9, e1003523		53
224	Glutamine and alanyl-glutamine increase RhoA expression and reduce Clostridium difficile toxin-a-induced intestinal epithelial cell damage. **2013**, 2013, 152052		10

223	Bacterial complications of respiratory tract viral illness: a comprehensive evaluation. **2013**, 208, 432-41		103
222	Management of febrile neutropenia in the era of bacterial resistance. **2013**, 1, 37-43		22
221	The microbiome andClostridium difficileinfection. **2013**, 46-59		
220	Risk factors, preemptive therapy, and antiperistaltic agents for Clostridium difficile infection in cancer patients. **2013**, 15, 493-501		11
219	Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic. **2013**, 1291, 33-41		18
218	Hype or hypervirulence: a reflection on problematic C. difficile strains. **2013**, 4, 592-6		35
217	Health care burden of Clostridium difficile infection in hospitalized children with inflammatory bowel disease. **2013**, 19, 1080-5		38
216	Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study. **2013**, 141, 189-94		39
215	Clostridium difficileColitis after Topical Ophthalmic Use of Levofloxacin. **2013**, 36, S5		1
214	Community-acquired Clostridium difficile infection: an increasing public health threat. **2014**, 7, 63-72		146
213	Factors associated with Clostridium difficile diarrhea in a hospital in Beijing, China. **2014**, 47, 1085-90		10
212	Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia. **2014**, 7, 819-30		23
211	Clostridium difficile infection: management strategies for a difficult disease. **2014**, 7, 72-86		35
210	Assessing control bundles for Clostridium difficile: a review and mathematical model. **2014**, 3, e43		22
209	Occurrence of Clostridium difficile infections due to PCR ribotype 027 in Bucharest, Romania. **2014**, 8, 694-8		10
208	Asymptomatic Clostridium difficile colonization as a reservoir for Clostridium difficile infection. **2014**, 12, 967-80		27
207	Treatment of bacteriobilia decreases wound infection rates after pancreaticoduodenectomy. **2014**, 16, 592-8		38
206	Enteric infections. *Cancer Treatment and Research*, **2014**, 161, 237-51	3.5	2

205	Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality. **2014**, 33, 1045-51		18
204	Infectious Complications in Cancer Patients. *Cancer Treatment and Research*, **2014**,	3.5	4
203	A cluster of fulminant Clostridium difficile colitis in an intensive care unit in Italy. **2014**, 42, 585-9		11
202	A review of the economics of treating Clostridium difficile infection. **2014**, 32, 639-50		22
201	Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. **2014**, 69, 881-91		343
200	Association between Clostridium difficile infection and antimicrobial usage in a large group of English hospitals. **2014**, 77, 896-903		7
199	Clostridium difficile Infection Update for the Hospital-Based Physician. **2014**, 2, 214-223		
198	Clostridium difficile: improving the prevention paradigm in healthcare settings. **2014**, 12, 1087-102		12
197	Impact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study. **2014**, 69, 341-351		25
196	The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move. *Clinical Microbiology and Infection*, **2014**, 20, 396-404	9.5	60
195	The evolution of urban C. difficile infection (CDI): CDI in 2009-2011 is less severe and has better outcomes than CDI in 2006-2008. *American Journal of Gastroenterology*, **2014**, 109, 1265-76	0.7	23
194	A retrospective analysis of clinical characteristics, hospitalization, and functional outcomes in residents with and without Clostridium difficile infection in US long-term care facilities. **2014**, 30, 1121-30		6
193	A population-based spatio-temporal analysis of Clostridium difficile infection in Queensland, Australia over a 10-year period. **2014**, 69, 447-55		18
192	Prevention of hospital-onset Clostridium difficile infection in the New York metropolitan region using a collaborative intervention model. **2014**, 36, 35-45		20
191	Investigation to identify a resource-efficient case-control methodology for determining antibiotics associated with Clostridium difficile infection. **2014**, 42, S264-8		3
190	Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials. **2014**, 69, 13-25		41
189	Overview and changing epidemiology of Clostridium difficile infection. **2014**, 25, 118-123		5
188	Fulminant colitis from Clostridium difficile infection, the epidemic strain ribotype 027, in Japan. **2014**, 20, 380-3		10

187	Control of Clostridium difficile infection in the hospital setting. **2014**, 12, 457-69		3
186	Role of doxycycline in Clostridium difficile infection acquisition. **2014**, 48, 772-6		11
185	Clostridium difficile infection among immunocompromised patients in Rio de Janeiro, Brazil and detection of moxifloxacin resistance in a ribotype 014 strain. **2014**, 28, 85-9		16
184	Epidemiology and outcomes of community-acquired Clostridium difficile infections in Medicare beneficiaries. **2014**, 218, 1141-1147.e1		29
183	Timing and type of surgical treatment of Clostridium difficile-associated disease: a practice management guideline from the Eastern Association for the Surgery of Trauma. **2014**, 76, 1484-93		42
182	WSES guidelines for management of Clostridium difficile infection in surgical patients. **2015**, 10, 38		60
181	Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea. **2015**, 2, e000028		15
180	[Treatment of a severe Clostridium difficile infection with colonic lavages. Report of one case]. **2015**, 143, 668-72		2
179	Gut Dysbiosis in Patients with Anorexia Nervosa. *PLoS ONE*, **2015**, 10, e0145274	3.7	119
178	Surgical Management of Severe Colitis in the Intensive Care Unit. **2015**, 30, 451-61		7
177	Association of Clostridium difficile infection in hospital mortality: A systematic review and meta-analysis. **2015**, 43, 1316-20		19
176	The morbidity, mortality, and costs associated with Clostridium difficile infection. **2015**, 29, 123-34		116
175	Missed diagnosis of Clostridium difficile infection; a prospective evaluation of unselected stool samples. **2015**, 70, 264-72		14
174	Risk of Clostridium difficile infection in intensive care unit patients with sepsis exposed to metronidazole. **2015**, 47, 197-202		4
173	Effects of fluoroquinolone restriction (from 2007 to 2012) on Clostridium difficile infections: interrupted time-series analysis. **2015**, 91, 74-80		39
172	Serum Procalcitonin Measurement and Viral Testing to Guide Antibiotic Use for Respiratory Infections in Hospitalized Adults: A Randomized Controlled Trial. **2015**, 212, 1692-700		82
171	Clostridium Difficile Infection from a Surgical Perspective. **2015**, 19, 1363-77		27
170	Clostridium difficile. **2015**, 181-206		1

169	Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections. **2015**, 59, 3848-52		59
168	Recurrent Clostridium difficile infection: From colonization to cure. **2015**, 34, 59-73		60
167	The evaluation of Clostridium difficile infection (CDI) in a community hospital. **2015**, 8, 155-60		9
166	Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis. *Infection Control and Hospital Epidemiology*, **2015**, 36, 452-60	2	146
165	Comparison of Clostridium difficile isolates from individuals with recurrent and single episode of infection. **2015**, 33, 105-8		17
164	Regional differences in Clostridium difficile infections in relation to fluoroquinolone and proton pump inhibitor use, Finland, 2008-2011. **2015**, 47, 530-5		6
163	Risk Factors for Acquisition and Loss of Clostridium difficile Colonization in Hospitalized Patients. **2015**, 59, 4533-43		36
162	Clostridium difficile infection (CDI) in children due to hypervirulent strains PCR-ribotype 027: An emblematic report of two cases. **2015**, 36, 91-3		3
161	Clostridium difficile ribotypes in Austria: a multicenter, hospital-based survey. **2015**, 127, 587-93		11
160	Incorrect diagnosis of Clostridium difficile infection in a university hospital in Japan. **2015**, 21, 718-22		26
159	Prevalence of ciprofloxacin-resistant Enterobacteriaceae in the intestinal flora of patients undergoing transrectal prostate biopsy in Norwich, UK. **2015**, 116, 131-4		8
158	An agent-based simulation model for Clostridium difficile infection control. **2015**, 35, 211-29		28
157	12. Clostridium difficile und andere gastrointestinale Infektionen. **2016**,		
156	A Multi-Faceted Approach of One Teaching Hospital NHS Trust during the Clostridium difficile Epidemic-Antibiotic Management and Beyond. **2016**, 5,		1
155	Antibacterial Resistance in Patients with Hematopoietic Stem Cell Transplantation. **2017**, 9, e2017002		8
154	Clinical Outcomes in Hospitalized Patients with Clostridium difficile Infection by Age Group. **2016**, 67, 81-6		13
153	Extended Perioperative Antibiotic Coverage in Conjunction with Intraoperative Bile Cultures Decreases Infectious Complications after Pancreaticoduodenectomy. **2016**, 2016, 3031749		11
152	Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. *World Journal of Gastroenterology*, **2016**, 22, 3078-104	5.6	81

151	Fecal Transplantation using a Nasoenteric Tube during an Initial Episode of Severe Clostridium difficile Infection. *Infection and Chemotherapy*, **2016**, 48, 31-5	3.9	4
150	Clinical characteristics of Clostridium difficile-associated diarrhea among patients in a tertiary care center in China. **2016**, 32, 736-41		6
149	Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial. *PLoS ONE*, **2016**, 11, e0152986	3.7	13
148	Assessing the Risk of Hospital-Acquired Clostridium Difficile Infection With Proton Pump Inhibitor Use: A Meta-Analysis. *Infection Control and Hospital Epidemiology*, **2016**, 37, 1408-1417	2	45
147	Clostridium difficile Infection. **2016**, 4,		9
146	Clostridium difficile Infection Is Associated With Lower Inpatient Mortality When Managed by GI Surgeons. **2016**, 59, 855-61		3
145	Integrating Time-Varying and Ecological Exposures into Multivariate Analyses of Hospital-Acquired Infection Risk Factors: A Review and Demonstration. *Infection Control and Hospital Epidemiology*, **2016**, 37, 411-9	2	6
144	Probiotics as adjunctive therapy for preventing Clostridium difficile infection - What are we waiting for?. **2016**, 41, 51-57		29
143	Clostridium difficile Infection. **2016**, 929-949		
142	Stress Ulcer Prophylaxis. **2016**, 44, 1395-405		44
141	Characterization of Clostridium difficile PCR-ribotype 018: A problematic emerging type. **2016**, 42, 123-129		14
140	Emerging Infectious Diseases. **2016**, 386-413		
139	Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). **2016**, 11, 33		95
138	The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. Administrative databases. **2016**, 16, 177		27
137	Novel approaches to treating Clostridium difficile-associated colitis. **2016**, 10, 193-204		5
136	Implementation of a penicillin allergy screening tool to optimize aztreonam use. **2016**, 73, 298-306		25
135	Hospital Clostridium difficile infection (CDI) incidence as a risk factor for hospital-associated CDI. **2016**, 44, 825-9		10
134	Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. **2016**, 3, 23-42		153

133	Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection. **2016**, 11, 657-65		28
132	Spectrum of Clostridium difficile infections: Particular clinical situations. **2016**, 37, 3-7		3
131	Memory B Cells Encode Neutralizing Antibody Specific for Toxin B from the Clostridium difficile Strains VPI 10463 and NAP1/BI/027 but with Superior Neutralization of VPI 10463 Toxin B. **2016**, 84, 194-204		11
130	Factors predictive of severe Clostridium difficile infection depend on the definition used. **2016**, 37, 43-8		21
129	Fecal Microbiota Transplant: Treatment Options for Clostridium difficile Infection in the Intensive Care Unit. **2016**, 31, 577-86		17
128	Nosocomial Clostridium difficile-associated diarrhoea in Assiut University Children's Hospital, Egypt. **2016**, 36, 39-44		7
127	A population-based longitudinal study of Clostridium difficile infection-related hospitalization in mid-age and older Australians. **2017**, 145, 575-582		6
126	Clostridium difficile. **2017**, 37, 341-369		21
125	Primary prevention of Clostridium difficile infections - how difficult can it be?. **2017**, 11, 507-521		8
124	Impact of Clostridium difficile infection caused by the NAP1/RT027 strain on severity and recurrence during an outbreak and transition to endemicity in a Mexican tertiary care center. **2017**, 65, 44-49		15
123	Healthcare-Associated Clostridium difficile Infections are Sustained by Disease from the Community. **2017**, 79, 2242-2257		12
122	The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease. **2017**, 52, 1240-1247		12
121	An Adaptive Phase 3 Trial for Evaluating Two Monoclonal Antibodies and the Combination for Prevention of Recurrence of C. difficile Infection. **2017**, 9, 361-367		
120	Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. *World Journal of Gastroenterology*, **2017**, 23, 6500-6515	5.6	118
119	[Characteristics of Clostridium difficile infection in a high complexity hospital and report of the circulation of the NAP1/027 hypervirulent strain in Colombia]. **2017**, 37, 466-472		9
118	Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). **2018**, 66, e1-e48		926
117	Antibiotic Resistances of Clostridium difficile. **2018**, 1050, 137-159		25
116	Nasogastric tube and outcomes of Clostridium difficile infection: A systematic review and meta-analysis. **2018**, 11, 40-45		3

115	Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. *Clinical Microbiology and Infection*, **2018**, 24, 749-754	9.5	9
114	Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study. **2018**, 37, 745-754		12
113	Unusual oral mucosal microbiota after hematopoietic cell transplantation with glycopeptide antibiotics: potential association with pathophysiology of oral mucositis. **2018**, 63, 587-597		7
112	Repeated Clostridium difficile infection after living donor liver transplantation. **2018**, 11, 309-311		1
111	Magnitude and direction of the association between Clostridium difficile infection and proton pump inhibitors in adults and pediatric patients: a systematic review and meta-analysis. **2018**, 53, 84-94		34
110	Clostridium difficile : What the surgeon needs to know. **2018**, 29, 28-36		1
109	Stress Ulcer Prophylaxis in Neurocritical Care. **2018**, 29, 344-357		7
108	Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. **2018**, 98, 4-13		44
107	[Preclinical and clinical properties of Bezlotoxumab (ZINPLAVA 25 mg/mL concentrate for solution for infusion), novel therapeutic agent for Clostridium difficile infection]. **2018**, 152, 39-50		1
106	Intrinsic Class D Lactamases of. **2018**, 9,		19
105	Predictive factors of Clostridioides difficile infection in hospitalized patients with new diarrhea: A retrospective cohort study. *PLoS ONE*, **2018**, 13, e0207128	3.7	1
104	Reprint of: Overview and changing epidemiology of Clostridium difficile infection. **2018**, 29, 206-211		1
103	Impact of an antimicrobial stewardship program on healthcare-associated rates at a community-based teaching hospital. **2018**, 19, 191-194		6
102	Antibacterial and Antifungal Agents: The Challenges of Antimicrobial-Resistant Infections in Immunocompromised Hosts. **2018**, 297-315		2
101	Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms. **2018**, 2018, 8414257		34
100	- From Colonization to Infection. **2018**, 9, 646		68
99	Outcomes of Clostridium difficile-suspected diarrhea in a French university hospital. **2018**, 37, 2123-2130		3
98	Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols. **2018**, 26, 4187-4198		10

97	Infection and Colorectal Surgery: Is There Any Risk?. **2019**, 55,		6
96	Antibiotic resistance of clinical isolates of Clostridioides difficile in China and its association with geographical regions and patient age. **2019**, 60, 102094		11
95	Antibiotic Consideration in Transplant Recipients. **2019**, 855-901		
94	Fluoroquinolone-related adverse events resulting in health service use and costs: A systematic review. *PLoS ONE*, **2019**, 14, e0216029	3.7	18
93	Efficacy of levofloxacin as an antibacterial prophylaxis for acute leukemia patients receiving intensive chemotherapy: a systematic review and meta-analysis. **2019**, 24, 362-368		9
92	2019 update of the WSES guidelines for management of () infection in surgical patients. **2019**, 14, 8		59
91	Designed Ankyrin Repeat Protein (DARPin) Neutralizers of TcdB from Clostridium difficile Ribotype 027. **2019**, 4,		7
90	Incidence Of Infection And Associated Risk Factors Among Hospitalized Children In Qatar. **2019**, 15, 1343-1350	2	
89	Prevention and treatment of recurrent Clostridioides difficile infection. **2019**, 32, 482-489		5
88	Antimicrobial susceptibility and mechanisms of resistance of Greek Clostridium difficile clinical isolates. **2019**, 16, 53-58		16
87	Effect of fluoroquinolone resistance mutation Thr-82-Ile on Clostridioides difficile fitness. **2019**, 74, 877-884		5
86	Fluoroquinolone Prophylaxis Is Highly Effective for the Prevention of Central Line-Associated Bloodstream Infections in Autologous Stem Cell Transplant Patients. **2019**, 25, 1004-1010		9
85	Temporal trends of inpatient infections within the Veterans Health Administration hospitals: An analysis of the effect of molecular testing, time to testing, and mandatory reporting. *Infection Control and Hospital Epidemiology*, **2020**, 41, 44-51	2	1
84	Incidence and Outcome of Clostridium difficile Infection-Beware of Strain Type and Diagnostic Tests. **2020**, 3, e1918599		
83	Bile cultures are poor predictors of antibiotic resistance in postoperative infections following pancreaticoduodenectomy. **2020**, 22, 969-978		3
82	Nosocomial Infections: A History of Hospital-Acquired Infections. **2020**, 30, 637-652		9
81	Molecular epidemiology of predominant and emerging Clostridioides difficile ribotypes. **2020**, 175, 105974		4
80	Risk Factors of Clostridium Difficile Infection After Spinal Surgery: National Health Insurance Database. **2020**, 10, 4438		3

79	When is an outbreak an outbreak? Using literature and discharge data to define Clostridioides difficile incidence changes referred to as outbreaks. **2020**, 105, 225-231	
78	Clostridioides difficile infection evaluation and management in the emergency department. **2020**, 38, 2203-2208	0
77	Genotypic correlation between post discharge Clostridiodes difficile infection (CDI) and previous unit-based contacts. **2021**, 109, 96-100	
76	Drug Effects on the Gastrointestinal System: A Physician Perspective. **2021**, 279-296	
75	Economic burden and cost-effectiveness of therapies for infection: a narrative review. **2021**, 14, 1756284821106	18654
74	Impact of Beta-Lactam Allergies on Selection of Antimicrobials in an Inpatient Setting Among Veteran Population. **2021**,	1
73	Epidemiology. **2021**, 35-47	
72	Risk Factors for CDI. **2021**, 49-59	
71	Endotoxin Acts Synergistically With Clostridioides difficile Toxin B to Increase Interleukin 1 Production: A Potential Role for the Intestinal Biome in Modifying the Severity of C. difficile Colitis. **2021**, 224, 1556-1565	1
70	Infections in Older Adults. **2021**, 39, 379-394	4
69	Antibiotic exposure and the risk of hospital-acquired diarrhoea and Clostridioides difficile infection: a cohort study. **2021**, 76, 2182-2185	2
68	Factors Associated with Clostridioides (Clostridium) Difficile Infection and Colonization: Ongoing Prospective Cohort Study in a French University Hospital. **2021**, 18,	2
67	Emerging Issues and Trends In Clostridium Difficile Colitis. **2009**, 189-225	1
66	Drug Effects on the Gastrointestinal Tract. **2012**, 73-81	2
65	Clostridium difficile and the disease it causes. **2010**, 646, 9-35	22
64	Antimicrobial Stewardship: Considerations for a Cancer Center. **2011**, 491-498	4
63	Controversies in Antimicrobial Stewardship. **2011**, 499-506	1
62	Infection Prevention and Control Issues After Solid Organ Transplantation. **2016**, 843-867	1

61	Infections In Palliative Medicine. **2009**, 505-509		1
60	Clostridium difficile in paediatric populations. *Paediatrics and Child Health*, **2014**, 19, 43-48	0.7	4
59	Repeated stool toxin testing for diagnosing difficile colitis is still valid. *Southern Medical Journal*, **2009**, 102, 993-4	0.6	2
58	Antimicrobial susceptibility of animal and human isolates of Clostridium difficile by broth microdilution. *Journal of Medical Microbiology*, **2013**, 62, 1478-1485	3.2	46
57	Human C. difficile toxin-specific memory B cell repertoires encode poorly neutralizing antibodies. *JCI Insight*, **2020**, 5,	9.9	3
56	IL-17-producing □T cells protect against Clostridium difficile infection. *Journal of Clinical Investigation*, **2020**, 130, 2377-2390	15.9	15
55	The association between histamine 2 receptor antagonist use and Clostridium difficile infection: a systematic review and meta-analysis. *PLoS ONE*, **2013**, 8, e56498	3.7	36
54	Tracing the Spread of Clostridium difficile Ribotype 027 in Germany Based on Bacterial Genome Sequences. *PLoS ONE*, **2015**, 10, e0139811	3.7	24
53	Identification of Medicare Recipients at Highest Risk for Clostridium difficile Infection in the US by Population Attributable Risk Analysis. *PLoS ONE*, **2016**, 11, e0146822	3.7	21
52	Surveillance of Antibiotic Resistance among Hospital- and Community-Acquired Toxigenic Clostridium difficile Isolates over 5-Year Period in Kuwait. *PLoS ONE*, **2016**, 11, e0161411	3.7	14
51	Experiences with fecal microbiota transplantation in infections via upper gastrointestinal tract. *Acta Microbiologica Et Immunologica Hungarica*, **2019**, 66, 179-188	1.8	4
50	[Experience with fecal transplantation in the treatment of Clostridium difficile infection]. *Orvosi Hetilap*, **2014**, 155, 1758-62	0.8	7
49	Dietary-based gut flora modulation againstClostridium difficileonset. *Food Science and Technology Bulletin*, **2007**, 4, 31-41		6
48	Predictors of Clostridium difficile infection severity in patients hospitalised in medical intensive care. *World Journal of Gastroenterology*, **2013**, 19, 8034-41	5.6	23
47	Current epidemiology and treatment ofClostridium difficileinfection. *Infection and Chemotherapy*, **2010**, 42, 362	3.9	5
46	in patients attending tuberculosis hospitals in Cape Town, South Africa, 2014-2015. *African Journal of Laboratory Medicine*, **2018**, 7, 846	0.9	7
45	Surveillance for Antibiotic Resistance in <i>Clostridium difficile</i> Strains Isolated from Patients in a Tertiary Care Center. *Advances in Microbiology*, **2015**, 05, 336-345	0.6	4
44	The simple predictors of pseudomembranous colitis in patients with hospital-acquired diarrhea: a prospective observational study. *Gut and Liver*, **2014**, 8, 41-8	4.8	7

43	Risk of Clostridium difficile Infection with the Use of a Proton Pump Inhibitor for Stress Ulcer Prophylaxis in Critically Ill Patients. *Gut and Liver*, **2016**, 10, 581-6	4.8	22
42	Comparison of the Hospital-Acquired Infection Risk of Using Proton Pump Inhibitors versus Histamine-2 Receptor Antagonists for Prophylaxis and Treatment of Stress Ulcers: A Systematic Review and Meta-Analysis. *Gut and Liver*, **2017**, 11, 781-788	4.8	24
41	ClostridiumdifficileInfection: What's New?. *Intestinal Research*, **2013**, 11, 1	4.1	8
40	Clostridium difficile Infections: What Every Clinician Should Know. **2010**, 14, 35-40		7
39	European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. *Clinical Microbiology and Infection*, **2021**,	9.5	32
38	Clostridium difficile Colitis: Reduced Time to Diagnosis in a Community-Based Outpatient Setting Between 1997 and 2004. **2007**, 11, 45-8		
37	ClostridiumdifficileInfection: Overview and Update with a Focus on Antimicrobial Resistance as a Risk Factor. *Infectious Disease and Therapy*, **2007**, 183-218		
36	Bacteria. **2009**, 71-112		
35	Clostridium and The Ageing Gut. **2009**, 223-262		
34	Proton Pump Inhibitor Use and Enteric Infections. *American Journal of Gastroenterology*, **2009**, 104, S10-S16	5.6	
33	Clostridium difficile. **2010**, 792-795.e1		
32	Evaluation of the Febrile Patient in the ICU. **2010**, 349-360		
31	Statin Use Associated With a Decreased Length of Hospital Stay in Diabetic Patients With Clostridium difficile Infection. *Endocrine Practice*, **2011**, 17, 150-152	3.2	
30	Factors that predict clinical outcome after colectomy for fulminant <i>Clostridium difficile</i> colitis. *Open Journal of Gastroenterology*, **2012**, 02, 51-55	0.2	
29	Infection control issues in Clostridium difficile. **2013**, 110-125		
28	Characteristics, Treatment, and Outcomes Associated with <i>Clostridium difficile</i> Associated Diarrhea in a Veterans Affairs Medical Center. *Advances in Infectious Diseases*, **2014**, 04, 1-7	0.9	
27	Le Clostridium difficile dans les populations d□ge p□diatrique. *Paediatrics and Child Health*, **2014**, 19, 49-54	0.7	
26	Infection control and prevention considerations. *Cancer Treatment and Research*, **2014**, 161, 463-83	3.5	1

25	Asymptomatic Carriers and Captive Audiences. 217-242		
24	Unique Antibacterial Agents. **2015**, 440-446.e2		1
23	Bacterial, Viral, and Toxic Causes of Diarrhea, Gastroenteritis, and Anorectal Infections. 1196-1248		
22	Clostridium difficileInfection. 265-294		1
21	Detection and characterization of Clostridium difficile infections tracking the trends of Clostridium difficile culture. **2016**, 22, 15-25		
20	Review of updated clinical practice guidelines of the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) for Clostridium difficile infection in adults and children (2017). *Kliniceskaa Mikrobiologia I Antimikrobnaa Himioterapia*, **2018**, 20, 76-124	1.3	1
19	Guidelines for Antibiotic Prescription in Intensive Care Unit. *Indian Journal of Critical Care Medicine*, **2019**, 23, S1-S63	1.3	12
18	Drug Effects on the Gastrointestinal System: A Physician Perspective. **2020**, 1-18		
17	Development and Validation of a web-based Postoperative Clostridioides difficile infection risk prediction model.		1
16	Epidemiology and virulence-associated genes of isolates and factors associated with toxin EIA results at a university hospital in Japan. *Access Microbiology*, **2020**, 2, acmi000086	1	2
15	Antibacterial and Antiparasitic Prophylaxis. *Hematologic Malignancies*, **2021**, 13-22	0	
14	Current Treatment Options for Severe Clostridium difficile-associated Disease. *Gastroenterology and Hepatology*, **2008**, 4, 134-9	0.7	5
13	Clostridium difficile in paediatric populations. *Paediatrics and Child Health*, **2014**, 19, 43-54	0.7	2
12	Trends in Disease: Epidemiology and Intervention. **2009**, 26, 211-220		4
11	Management of Infection. *Gastroenterology and Hepatology*, **2016**, 12, 609-616	0.7	8
10	Clostridium Difficile Associated Disease: Burden of and Predictors for in Hospital Fatal Outcome. Results of a Hospital-Based Study, Bucharest, Romania. *M□dica*, **2015**, 10, 97-100		
9	Aspiration syndromes and associated lung injury: incidence, pathophysiology and management. *Physiological Research*, **2021**, S567-S583	2.1	
8	Association of fluoroquinolones or cephalosporin plus macrolide with infection (CDI) after treatment for community-acquired pneumonia.. *Infection Control and Hospital Epidemiology*, **2022**, 1-8	2	

7	Aspiration syndromes and associated lung injury: incidence, pathophysiology and management.. *Physiological Research*, **2021**, 70, S567-S583	2.1
6	Penicillin Binding Protein Substitutions Co-occur with Fluoroquinolone Resistance in â€Epidemicâ€ Lineages of Multi Drug-Resistant Clostridioides difficile.	
5	Clostridioides difficile Infection in Hospitalized Pediatric Patients: Comparisons of Epidemiology, Testing, and Treatment from 2013-2019. **2022**,	
4	Epidemiology of Clostridium (Clostridioides) difficile Infection in Southeast Asia. **2022**,	
3	Molecular epidemiology of Clostridioides difficile in companion animals: Genetic overlap with human strains and public health concerns. 10,	1
2	Prophylactic Trimethoprim-Sulfamethoxazole for Allogeneic Hematopoietic Stem Cell Transplant Recipients During the Pre-engraftment Period.	0
1	Penicillin Binding Protein Substitutions Cooccur with Fluoroquinolone Resistance in Epidemic Lineages of Multidrug-Resistant Clostridioides difficile.	0